Reisa Sperling, MD Elected to National Academy of Medicine
Dr. Reisa Sperling, has been elected to the National Academy of Medicine (NAM) for her pioneering clinical research that revolutionized the concept of preclinical Alzheimer’s disease.
I am a board certified neurologist who has been working in aging and Alzheimer's Disease (AD) imaging research for 15 years. My laboratory is focused on elucidating the neural underpinnings of memory loss in early Alzheimer's disease (AD) and developing neuroimaging markers of progression in preclinical and prodromal stages of AD. My work includes multiple imaging modalities including functional and structural MRI and PET amyloid imaging. I serve as the Director of the Neuroimaging Program at the Massachusetts Alzheimer's Disease Research Center (ADRC) at Massachusetts General Hospital. I also lead the AD clinical trials program across Brigham and Women's Hospital and Massachusetts General Hospital. I serve on the Steering committee of the Alzheimer's Disease Cooperative Study (ADCS), the Alzheimer's Disease Neuroimaging Initiative (ADNI), and the Dominantly Inherited Alzheimer Network (DIAN), and have the honor of chairing the National Institute on Aging/Alzheimer's Association Workgroup on Preclinical AD.
Clinical Interests:
Treats:
Massachusetts General Hospital
55 Fruit St.
Boston, MA 02114
Phone: 617-726-2000
Medical Education
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
Dr. Reisa Sperling, has been elected to the National Academy of Medicine (NAM) for her pioneering clinical research that revolutionized the concept of preclinical Alzheimer’s disease.
Can anti-amyloid antibody treatment reverse Alzheimer’s disease pathology before memory loss sets in?